Articles by Michael H Olsen

Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy

Olsen, Michael H; Wachtell, Kristian; Ibsen, Hans; More

Journal of Hypertension. 29(5):997-1004, May 2011.

In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the...

Wachtell, Kristian; Gerdts, Eva; Palmieri, Vittorio; More

Journal of Hypertension. 28(7):1541-1546, July 2010.

Agreement within Europe about antihypertensive treatment and education – results from the European Society of Hypertension questionnaire

Olsen, Michael H; Mallion, Jean-Michel; Rahn, Karl-Heinz; More

Journal of Hypertension. 28(7):1593-1594, July 2010.

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

Mancia, Giuseppe; Laurent, Stéphane; Agabiti-Rosei, Enrico; More

Journal of Hypertension. 27(11):2121-2158, November 2009.

Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex

Olsen, Michael H; Hansen, Tine W; Christensen, Marina K; More

Journal of Hypertension. 26(1):26-34, January 2008.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies

Eijkelkamp, Wouter BA; Zhang, Zhongxin; Brenner, Barry M; More

Journal of Hypertension. 25(4):871-876, April 2007.

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy

Olsen, Michael H; Wachtell, Kristian; Nielsen, Olav W; More

Journal of Hypertension. 24(8):1531-1539, August 2006.

High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors

Olsen, Michael H; Christensen, Marina K; Hansen, Tine W; More

Journal of Hypertension. 24(4):655-661, April 2006.

Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy

Olsen, Michael H; Wachtell, Kristian; Tuxen, Christian; More

Journal of Hypertension. 23(5):1083-1090, May 2005.

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Olsen, Michael H; Fossum, Eigil; Høieggen, Aud; More

Journal of Hypertension. 23(4):891-898, April 2005.

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Ibsen, Hans; Wachtell, Kristian; Olsen, Michael H; More

Journal of Hypertension. 22(9):1805-1811, September 2004.

N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study

Olsen, Michael H; Wachtell, Kristian; Tuxen, Christian; More

Journal of Hypertension. 22(8):1597-1604, August 2004.